Rani Therapeutics, based in San Jose, USA, announced that RaniPill, a biomacromolecular delivery capsule developed by the company, demonstrated good safety and tolerability in its first human trial. The company plans to launch further clinical trials later this year to test the effects of RaniPill delivery drugs in humans. Perhaps the future of oral biologics is not far from us.